Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Sclerosis Association with Malignancy.
Lepri G, Catalano M, Bellando-Randone S, Pillozzi S, Giommoni E, Giorgione R, Botteri C, Matucci-Cerinic M, Antonuzzo L, Guiducci S. Lepri G, et al. Among authors: giorgione r. Clin Rev Allergy Immunol. 2022 Dec;63(3):398-416. doi: 10.1007/s12016-022-08930-4. Epub 2022 Sep 19. Clin Rev Allergy Immunol. 2022. PMID: 36121543 Free PMC article. Review.
Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R. Palmieri VE, et al. Among authors: giorgione r. Expert Rev Clin Pharmacol. 2021 May;14(5):535-544. doi: 10.1080/17512433.2021.1901580. Epub 2021 Mar 21. Expert Rev Clin Pharmacol. 2021. PMID: 33685318 Review.
Occurrence of Dysgeusia in Patients Being Treated for Cancer.
Di Meglio J, Dinu M, Doni L, Rossi G, Giorgione R, Colombini B, Antonuzzo L, Sofi F. Di Meglio J, et al. Among authors: giorgione r. Nutr Cancer. 2022;74(8):2868-2874. doi: 10.1080/01635581.2022.2042569. Epub 2022 Feb 23. Nutr Cancer. 2022. PMID: 35196919
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer.
DI Maida F, Grosso AA, Tellini R, Lambertini L, Lo Re M, Cadenar A, Giudici S, Giorgione R, Rossi V, Antonuzzo L, Minervini A, Mari A. DI Maida F, et al. Among authors: giorgione r. Minerva Urol Nephrol. 2022 Oct;74(5):642-646. doi: 10.23736/S2724-6051.22.04959-X. Minerva Urol Nephrol. 2022. PMID: 36125025 Free article. No abstract available.
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: giorgione r. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
11 results